Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TSC 201

Drug Profile

TSC 201

Alternative Names: TSC-201

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TScan Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Anal cancer; Head and neck cancer; Macroglobulinaemia; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 25 Apr 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in USA (Parenteral) (TScan Therapeutics pipeline, April 2024) (NCT05973487)
  • 25 Apr 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Parenteral) (TScan Therapeutics pipeline, April 2024) (NCT05973487)
  • 06 Mar 2024 Tscan Therapeutics plans a phase I trial for Solid tumours in the first quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top